4 minute read
Mar. 13, 2023

Deucravacitinib: a First-In-Class Oral, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor

BMS TYK2 inhibitor

first-in-class oral, allosteric TYK2 inhibitor FDA-approved for moderate-to-severe plaque psoriasis opt. + SBDD of in-house phenotypic HTS hit deucravacitinib (BMS-986165, SOTYKTU) Bristol Myers Squibb, New York, NY

drughunter.com
Drug Hunter Team

Deucravacitinib (Sotyktu) is a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor, FDA-approved in September 2022 for moderate-to-severe plaque psoriasis. It is the first novel oral therapy for this indication in nearly 10 years, and is believed to potentially become the new standard of care. Deucravacitinib is the first de [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in